Koyfin Home > Directory > Health Care > Amag Pharmaceuticals > EBITDA

Amag Pharmaceuticals EBITDA Chart (AMAG)

Amag Pharmaceuticals annual/quarterly EBITDA from 2010 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Amag Pharmaceuticals EBITDA for the quarter ending June 06, 2020 was $-13m a -3.87% increase of 0m year over year
  • Amag Pharmaceuticals EBITDA for the last 12 months ending June 06, 2020 was $-74m a -38.09% increase of 28m year over year
  • Amag Pharmaceuticals Annual EBITDA for 2019 was $-114m a 185.48% decrease of -212m from 2018
  • Amag Pharmaceuticals Annual EBITDA for 2018 was $98m a -69.47% decrease of -68m from 2017
  • Amag Pharmaceuticals Annual EBITDA for 2017 was $166m a -36.90% decrease of -61m from 2016
Other Income Statement Metrics:
  • Amag Pharmaceuticals Net Income for the quarter ending December 12, 2018 was $-22m a -143.49% increase of 32m year over year
  • Amag Pharmaceuticals Total Revenue for the quarter ending September 09, 2018 was $122m a -29.53% decrease of -36m year over year
View Chart On Koyfin

Quarterly AMAG EBITDA Data

06/2020$-13m
03/2020$-17m
12/2019$-41m
09/2019$-13m
06/2019$-33m
03/2019$-35m
12/2018$-15m
09/2018$25m
06/2018$59m
03/2018$29m

Annual AMAG EBITDA Data

2019$-114m
2018$98m
2017$166m
2016$227m
2015$200m
2014$15m
2013$-5m
2012$-11m
2011$-69m
2010$-78m